Concepedia

Author

Leslie Amass

Pfizer (United States)

Also Known As

Amass, Leslie, L Amass, L. Amass, LESLIE AMASS, Leslie Amass

95

Publications

4.1K

Citations

36

H-Index

90

Concepts

All Affiliations

Pfizer (United States)University of VermontColumbia UniversityUniversidade Federal do Rio de JaneiroFriends Research Institute
LA

About

Leslie Amass is an author at Pfizer (United States) specializing in medicine, addiction, and addiction medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

27

1.9K

2

Health Sciences

16

18

1.4K

3

Education

1

1

27

4

Natural Sciences

1

1

69

5

Nursing

1

1

25

Leslie Amass

×

59

Publications

3.6K

Citations

35

H-Index

YearCitations

A multi‐center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network

Walter Ling, Leslie Amass, Steven Shoptaw,

Addiction

2005

230

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

Hartmut Schmidt, Márcia Waddington‐Cruz, Marc Botteman,

Muscle & Nerve

2017

205

Effects of adding behavioral treatment to opioid detoxification with buprenorphine.

Warren K. Bickel, Leslie Amass, Stephen T. Higgins,

Journal of Consulting and Clinical Psychology

1997

168

Effects of adding behavioral treatment to opioid detoxification with buprenorphine.

Warren K. Bickel, Leslie Amass, Stephen T. Higgins,

Journal of Consulting and Clinical Psychology

1997

153

Buprenorphine treatment of opioid dependence: A review.

Warren K. Bickel, Leslie Amass

Experimental and Clinical Psychopharmacology

1995

150

Bringing Buprenorphine‐Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

Leslie Amass, Walter Ling, Thomas E. Freese,

American Journal on Addictions

2004

148

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet

Leslie Amass, Jonathan B. Kamien, Susan K. Mikulich

Drug and Alcohol Dependence

2000

130

Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years

Fábio Barroso, Daniel P. Judge, Ben Ebede,

Amyloid

2017

109

Acute alcohol effects on plasma estradiol levels in women

Jack H. Mendelson, Scott E. Lukas, Nancy K. Mello,

Psychopharmacology

1988

105

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers

Sandra D. Comer, Maria A. Sullivan, Suzanne K. Vosburg,

Addiction

2010

103

Page 1